D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 120 Citations 64,695 400 World Ranking 119 National Ranking 82
Medicine D-index 122 Citations 68,637 444 World Ranking 1397 National Ranking 843

Research.com Recognitions

Awards & Achievements

2008 - Member of the National Academy of Sciences

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Antibody

His scientific interests lie mostly in Immunology, Antibody, Lymphoma, Follicular lymphoma and Immune system. His biological study spans a wide range of topics, including Molecular biology, B-cell lymphoma, Toxicity and Virology. Many of his studies involve connections with topics such as Monoclonal and Lymphoma.

His Follicular lymphoma study combines topics in areas such as Mutation, Tumor progression, Cancer research and Immunoglobulin G. His Immune system research is multidisciplinary, relying on both Cancer and Ex vivo. Ronald Levy focuses mostly in the field of Diffuse large B-cell lymphoma, narrowing it down to topics relating to BCL6 and, in certain cases, Gene expression profiling.

His most cited work include:

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (8095 citations)
  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (2532 citations)
  • Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells (1729 citations)

What are the main themes of his work throughout his whole career to date?

Ronald Levy mainly focuses on Immunology, Antibody, Lymphoma, Cancer research and Antigen. His research on Immunology frequently links to adjacent areas such as Cytotoxic T cell. The concepts of his Antibody study are interwoven with issues in Molecular biology and B-cell lymphoma.

Follicular lymphoma, Diffuse large B-cell lymphoma and Rituximab are the subjects of his Lymphoma studies. His studies deal with areas such as BCL6 and Oncology as well as Diffuse large B-cell lymphoma. His research in Cancer research intersects with topics in Cancer, Mantle cell lymphoma, Germinal center and Ibrutinib.

He most often published in these fields:

  • Immunology (42.86%)
  • Antibody (32.99%)
  • Lymphoma (31.80%)

What were the highlights of his more recent work (between 2016-2021)?

  • Cancer research (24.83%)
  • Lymphoma (31.80%)
  • Immune system (19.90%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Cancer research, Lymphoma, Immune system, Immunotherapy and Antibody. Ronald Levy has researched Cancer research in several fields, including Cancer, CD8 and T cell. His Lymphoma study combines topics from a wide range of disciplines, such as Ibrutinib and Oncology.

The study incorporates disciplines such as Peripheral blood mononuclear cell and Vaccination in addition to Immune system. Immunology covers Ronald Levy research in Antibody. His work on Acquired immune system as part of general Immunology study is frequently linked to Extramural, bridging the gap between disciplines.

Between 2016 and 2021, his most popular works were:

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (1549 citations)
  • Eradication of spontaneous malignancy by local immunotherapy (183 citations)
  • Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody (140 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Immune system

His primary areas of study are Cancer research, Immune system, Lymphoma, Cancer and Antibody. His Cancer research study incorporates themes from Cytotoxic T cell, CD8 and Immunotherapy. Ronald Levy combines subjects such as Progression-free survival and Oncology with his study of Lymphoma.

In the field of Cancer, his study on Cancer immunotherapy overlaps with subjects such as TLR9. His Antibody study is concerned with Immunology in general. The Immunoglobulin Idiotypes, Immunoglobulin genes, Somatic hypermutation and HLA-D Antigens research Ronald Levy does as part of his general Immunology study is frequently linked to other disciplines of science, such as Extramural, therefore creating a link between diverse domains of science.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos.
Nature (2000)

10864 Citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

P McLaughlin;A J Grillo-López;B K Link;R Levy.
Journal of Clinical Oncology (1998)

3383 Citations

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

Frank J. Hsu;Claudia Benike;Francesco Fagnoni;Tina Marie Liles.
Nature Medicine (1996)

2815 Citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney;Antonio J. Grillo-López;Christine A. White;David Bodkin.
Blood (1997)

2035 Citations

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis.
The New England Journal of Medicine (2017)

1958 Citations

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Wen-Kai Weng;Ronald Levy.
Journal of Clinical Oncology (2003)

1480 Citations

Two populations of Ia-like molecules on a human B cell line.

L A Lampson;R Levy.
Journal of Immunology (1980)

1337 Citations

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

Richard A. Miller;David G. Maloney;Roger Warnke;Ronald Levy.
The New England Journal of Medicine (1982)

1241 Citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

DG Maloney;TM Liles;DK Czerwinski;C Waldichuk.
Blood (1994)

1165 Citations

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

Izidore S. Lossos;Debra K. Czerwinski;Ash A. Alizadeh;Mark A. Wechser.
The New England Journal of Medicine (2004)

1007 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ronald Levy

Randy D. Gascoyne

Randy D. Gascoyne

BC Cancer Agency

Publications: 178

Louis M. Staudt

Louis M. Staudt

National Institutes of Health

Publications: 153

Andreas Rosenwald

Andreas Rosenwald

University of Würzburg

Publications: 121

Gilles Salles

Gilles Salles

Memorial Sloan Kettering Cancer Center

Publications: 118

Oliver W. Press

Oliver W. Press

Fred Hutchinson Cancer Research Center

Publications: 115

John G. Gribben

John G. Gribben

Queen Mary University of London

Publications: 106

Freda K. Stevenson

Freda K. Stevenson

University of Southampton

Publications: 106

Elaine S. Jaffe

Elaine S. Jaffe

National Institutes of Health

Publications: 105

Elias Campo

Elias Campo

University of Barcelona

Publications: 100

John C. Byrd

John C. Byrd

University of Cincinnati

Publications: 100

Stephen M. Ansell

Stephen M. Ansell

Mayo Clinic

Publications: 91

David M. Goldenberg

David M. Goldenberg

Pennsylvania State University

Publications: 83

Jan Delabie

Jan Delabie

University Health Network

Publications: 82

Larry W. Kwak

Larry W. Kwak

City Of Hope National Medical Center

Publications: 81

Irving L. Weissman

Irving L. Weissman

Stanford University

Publications: 79

German Ott

German Ott

Robert Bosch (Germany)

Publications: 78

Trending Scientists

Jan Rutten

Jan Rutten

Radboud University Nijmegen

Danny H. K. Tsang

Danny H. K. Tsang

Hong Kong University of Science and Technology

Simon R. Kelemen

Simon R. Kelemen

ExxonMobil (United States)

Zeev Valy Vardeny

Zeev Valy Vardeny

University of Utah

Roy L. Silverstein

Roy L. Silverstein

Medical College of Wisconsin

Naomi Kitamura

Naomi Kitamura

Tokyo Institute of Technology

Hari B. Krishnan

Hari B. Krishnan

University of Missouri

Roman Pallares

Roman Pallares

University of Barcelona

E. Richard Moxon

E. Richard Moxon

University of Oxford

Richard G. J. Bellerby

Richard G. J. Bellerby

East China Normal University

Alkiviadis F. Bais

Alkiviadis F. Bais

Aristotle University of Thessaloniki

Juan R. Bustillo

Juan R. Bustillo

University of New Mexico

Lars Å. Hanson

Lars Å. Hanson

University of Gothenburg

Karl Christoph Klauer

Karl Christoph Klauer

University of Freiburg

Geoffrey S. Ginsburg

Geoffrey S. Ginsburg

Duke University

Flora Peyvandi

Flora Peyvandi

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Something went wrong. Please try again later.